Channel Therapeutics Corporation

Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Channel Therapeutics Corporation trades as CHRO on AMEX. The company is classified in Healthcare / Biotechnology and reports in USD.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $16.80M of revenue and -$43.32M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Channel Therapeutics Corporation can be compared against peers such as Apexigen, Inc., Biora Therapeutics, Inc., CervoMed Inc., COSCIENS Biopharma Inc., IMV Inc., ObsEva S.A..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $8.90M, beta of 3.29, and return on equity of -111.4%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CHRO currently shows total debt of $34.19M and beta of 3.29. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 8-K (2026-05-28 00:00:00), 4 (2026-05-26 00:00:00), 144 (2026-05-22 00:00:00), 8-K (2026-05-21 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://channeltherapeutics.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.